Mobile

Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects with Moderate to Severe, Chronic Plaque-Type Psoriasis Sicurezza ed efficacia di Secukinumab in confronto a Etarnecerpt in ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2010-022228-66

Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects with Moderate to Severe, Chronic Plaque-Type Psoriasis Sicurezza ed efficacia di Secukinumab in confronto a Etarnecerpt in soggetti con psoriasi cronica a placche da moderata a severa

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Efficacy of secukinumab compared to placebo in subjects with moderate to severe chronic plaque-type psoriasis over 12 weeks based on PASI and IGA Dimostrare la superiorità di secukinumab rispetto al placebo alla Settimana 12, in soggetti con psoriasi cronica a placche da moderata a severa secondo la risposta PASI 75 e la valutazione IGA 0 o 1 (endpoint co-primari) .

Critère d'inclusion

  • Moderate to severe chronic plaque-type psoriasis,psoriasi cronica a placche da moderata a severa

Liens